Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Background: Von Hippel–Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue. Methods: Patients with VHL were given four cycles of 50 mg sunitinib dai...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Jonasch, E., McCutcheon, I. E., Waguespack, S. G., Wen, S., Davis, D. W., Smith, L. A., Tannir, N. M., Gombos, D. S., Fuller, G. N., Matin, S. F.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2011
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542805/
https://ncbi.nlm.nih.gov/pubmed/22105611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdr011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars